drugset / Trial / NCT05083000
Reducing Hypoxia in Patients With Coronavirus Disease (COVID-19) Using Topotecan With Standard of Care
Phase 1
Unknown
24 enrolled
National University Hospital, Singapore
Christian Medical College, Vellore, India · collab
NaSequentialOpen-labelTreatment
Summary
The primary objective of the phase 1 trial is to identify a dose of topotecan that will be safe to take forward into a Phase 2 trial, with no unexpected toxicities or drug-drug interactions with standard therapy for COVID-19. The investigators hypothesise that a single dose of low-dose Topotecan will blunt the expression of inflammatory genes in patients with moderate COVID-19, without cytotoxic side effects.
Timeline
- Start
- 2021-08-16
- Primary completion
- 2021-12-31
- Completion
- 2022-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Topotecan | Small molecule | 0.25 mg | Intravenous |
| Subject | Topotecan | Small molecule | 0.5 mg | Intravenous |